Data released at the 2022 EULAR Congress in Copenhagen has revealed results from the GAMER study.
Bart Pouls and colleagues assessed the effectiveness of a serious game compared to usual care to improve adherence to disease-modifying antirheumatic drugs (DMARDs) in 229 patients with RA. Participants in the intervention group were invited to play the serious puzzle game at will.
This randomized clinical trial was performed with a 3-month follow-up period. Of the 85 intervention participants, 82% played the game for at least 1 hour, with median overall playtime of 9.7 hours. Overall, 69% of intervention participants showed at least 40 days of gaming activity.
Key findings suggest that medication adherence in the control and intervention groups did not differ at 3 months, and there was no change in beliefs about medication or clinical outcomes.